*** THIS IS A PRESS RELEASE ***
The cell model study examined the response of several types of cancer cells to CannaboBreast products developed by Cannabotech, with a product based on fungal extract and their activity in conjunction with standard chemotherapies;
The study was conducted under the guidance of Prof. Tami Peretz, Senior Oncologist at Hadassah Medical Center, former director of the Oncology Institute and former director of the Center for Malignant Breast Diseases at Hadassah Medical Center, and Dr. Isaac Angel, pharmacologist specializing in drug development;
Herzliya, Israel – December 20, 2021 – Cannabotech, which is engaged in, among other things, the development of medical products based on cannabis and fungal extracts, reports the results of a cell model study examining the efficacy of CannaboBreast products intended for integrative and/or concomitant oncology treatment with drug protocols (chemotherapy, biological and hormonal) for breast cancer. (Killing Cancer Cells)
The CannaboBreast product series is based on a unique combination of cannabinoids and terpenes from the cannabis plant. In parallel, Cannabotech intends to produce a treatment program that combines CannaboBreast products and nutritional supplements based on active ingredients extracted from several fungi. According to the study results, the composition of cannabinoids in combination with standard chemotherapy improved the effectiveness up to 6 times in killing cancer cells compared to existing treatment (from 10% mortality to 60% mortality of cancer cells).
The results showed that in addition to the effectiveness in killing cancer cells (as shown in the previous experiment in July), they have a synergistic effect in combination with oncological drug treatments that have been tested in known subtypes of breast cancer, while a specific treatment was adapted to each subtype. Along with the ability to increase existing treatments’ effectiveness, it may be possible to achieve increased efficacy of killing breast cancer cells while significantly reducing chemotherapy doses, which is also expected to dramatically reduce side effects and enable healing for more patients who currently cannot undergo conventional treatment due to the side effects.
The experiment also emphasized the importance of tailoring treatment, applying CannaboBreast products to different breast cancer subtypes, achieving other medical effects in combination with the appropriate drugs for each subtype. For example, while in some chemotherapy treatments a synergistic effect was achieved which enhanced the activity, in other cells representing different cancers, or in combination with other chemotherapies, no similar effect was seen, and even an opposite effect was achieved. In addition, Cannabotech is also developing a personalization system to provide physicians with the knowledge with which drug treatments and sub-cancer types should CannaboBreast products be combined.
The treatment is expected to be commercialized in the second half of 2022 and be integrated as part of Cannabotech’s integrative solutions concept, which are designed to incorporate existing treatment protocols in parallel with conventional drugs while providing supportive scientific information to the clinic physicians. About 50% of breast cancer patients receive additional integrative treatment in addition to conventional treatment (mainly herbal products, including cannabis), with one of the reasons for using the integrative product being to strengthen the immune system to improve the effectiveness of treatment and reduce side effects.,
Cannabotech CEO Elchanan Shaked said: “This is a significant milestone in Cannabotech’s growth to becoming a leader in integrative medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment in several cancers and are expected to be launched in Israel and the US in the second half of 2022, while the Company’s goal is to define a new standard for the medical cannabis industry. “
Prof. Tami Peretz, Senior Oncologist: “A significant proportion of active cancer patients are currently treated with cannabis in parallel with conventional treatment. The integrative products developed by Cannabotech are unique in that they are developed to standards similar to those of the pharmaceutical industry and combine several active agents. The company’s products have demonstrated impressive and very promising activity in laboratory-tested cell cultures. Based on these experiments, there is room to start exploring the possibility of integrating the products in the treatment of breast cancer patients as well.”
Dr. Isaac Angel, Cannabotech’s pharmacological consultant, said: “The strong synergistic effect shown by the products in combination with the chemotherapies in different types of breast cancer cells has led to up to 6 times the effectiveness in cells killing. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products. We will continue to work to provide a cure for patients.”
Cannabotech is an Israeli biomedical company that develops botanical solutions for preventive medicine and integrative medicine. These solutions are based on combinations of active agents from the cannabis plant and fungi that work on two central systems in the human body: the endocannabinoid system and the immune system.
As part of the concept of integrative medicine, in the last two years, Cannabotech has been developing a series of 8 preparations designed to help patients with cancer and chronic pain based on unique combinations of botanicals from medical cannabis and fungus-based products. Upon completion of their development, the company’s goal is to designate the products to be integrated into oncology patients’ existing treatment protocol.
At the same time, Cannabotech is working to develop a defined treatment protocol made available to physicians and technology for treatment customization.
*** END OF PRESS RELEASE **
We would like to remind you that by subscribing to the THC Weekly newsletter you are the first to learn about new and exciting cannabinoid. Subscribe today and get our exclusive discounts on Delta 8, Delta 9, Delta 10 THC, THC-P, THC-O, HHC, THCV and other hemp-derived THC products.